Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Foundation Medicine Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Foundation Medicine Inc, Medical Devices Deals, 2011 to YTD 2017 10
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Foundation Medicine Raises US$56 Million In Series B Financing 13
Foundation Medicine Secures Additional US$8.5 Million In Series A Venture Financing 15
Foundation Medicine Raises US$10 Million In Venture Financing 16
Partnerships 17
Bristol-Myers Squibb Enters into Agreement with Foundation Medicine 17
Epizyme Enters into Agreement with Foundation Medicine 18
Foundation Medicine Enters into Agreement with AstraZeneca 19
Foundation Medicine Partners with AstraZeneca 20
Foundation Medicine Enters into Agreement with Mirati Therapeutics 21
Foundation Medicine Extends its Co-Development Agreement with H3 Biomedicine 22
Roche Amends R&D Agreement with Foundation Medicine 23
Foundation Medicine Enters into Co-Development Agreement with Flatiron Health 24
Foundation Medicine Enters Into Distribution Agreement With Laboratorios Leti 25
Foundation Medicine Expands Co-Development Agreement With Novartis 26
Foundation Medicine Enters Into Agreement With Agios Pharma To Develop Cancer Diagnostics 27
Foundation Medicine Enters Into Agreement With AstraZeneca For Genomic Profiling 28
Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 29
Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 30
Equity Offering 31
Foundation Medicine Raises USD250 Million in Private Placement of Shares 31
Foundation Medicine Withdraws Public Offering Of Shares For Up To US$150 Million 32
Foundation Medicine Completes IPO Of Shares For US$122 Million 33
Acquisition 34
Roche Acquires Majority Stake in Foundation Medicine for USD1.03 Billion 34
Foundation Medicine Inc – Key Competitors 36
Foundation Medicine Inc – Key Employees 37
Foundation Medicine Inc – Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 39
Financial Announcements 39
Nov 01, 2017: Foundation Medicine Announces 2017 Third Quarter Results and Recent Highlights 39
Aug 01, 2017: Foundation Medicine Announces 2017 Second Quarter Results and Recent Highlights 40
May 09, 2017: Foundation Medicine Announces 2017 First Quarter Results and Recent Highlights 42
Feb 22, 2017: Foundation Medicine Announces 2016 Fourth Quarter and Year-End Results, Recent Highlights and 2017 Outlook 44
Jan 09, 2017: Foundation Medicine Reports Preliminary 2016 Results 45
Nov 02, 2016: Foundation Medicine Announces 2016 Third Quarter Results and Recent Highlights 47
Aug 02, 2016: Foundation Medicine Announces 2016 Second Quarter Results and Recent Highlights 49
May 03, 2016: Foundation Medicine Announces 2016 First Quarter Results and Recent Highlights 51
Feb 23, 2016: Foundation Medicine Announces 2015 Fourth Quarter and Year-End Results, Recent Highlights and 2016 Outlook 52
Jan 11, 2016: Foundation Medicine Reports Preliminary 2015 Results and Provides 2016 Business Outlook, including Commercial Launch of its ctDNA Assay 53
Corporate Communications 54
Oct 10, 2017: Foundation Medicine Appoints Tom Civik as Chief Commercial Officer 54
Jan 06, 2017: Foundation Medicine Announces Executive Leadership Transition 55
Oct 27, 2016: Foundation Medicine Adds Life Sciences Leader Michael R. Dougherty to its Board of Directors 56
Product News 57
Oct 18, 2016: The Leukemia & Lymphoma Society Launches Groundbreaking Precision Medicine Approach to Treat Acute Myeloid Leukemia, One of the Deadliest Blood Cancers 57
Other Significant Developments 59
Feb 25, 2016: Foundation Medicine Announces First-Ever Public Release of Broad Pediatric Data From FoundationCORE to Accelerate the Development of Precision Medicine Strategies for Pediatric Cancers 59
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Foundation Medicine Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Foundation Medicine Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Foundation Medicine Inc, Medical Devices Deals, 2011 to YTD 2017 10
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Foundation Medicine Raises US$56 Million In Series B Financing 13
Foundation Medicine Secures Additional US$8.5 Million In Series A Venture Financing 15
Foundation Medicine Raises US$10 Million In Venture Financing 16
Bristol-Myers Squibb Enters into Agreement with Foundation Medicine 17
Epizyme Enters into Agreement with Foundation Medicine 18
Foundation Medicine Enters into Agreement with AstraZeneca 19
Foundation Medicine Partners with AstraZeneca 20
Foundation Medicine Enters into Agreement with Mirati Therapeutics 21
Foundation Medicine Extends its Co-Development Agreement with H3 Biomedicine 22
Roche Amends R&D Agreement with Foundation Medicine 23
Foundation Medicine Enters into Co-Development Agreement with Flatiron Health 24
Foundation Medicine Enters Into Distribution Agreement With Laboratorios Leti 25
Foundation Medicine Expands Co-Development Agreement With Novartis 26
Foundation Medicine Enters Into Agreement With Agios Pharma To Develop Cancer Diagnostics 27
Foundation Medicine Enters Into Agreement With AstraZeneca For Genomic Profiling 28
Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 29
Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 30
Foundation Medicine Raises USD250 Million in Private Placement of Shares 31
Foundation Medicine Withdraws Public Offering Of Shares For Up To US$150 Million 32
Foundation Medicine Completes IPO Of Shares For US$122 Million 33
Roche Acquires Majority Stake in Foundation Medicine for USD1.03 Billion 34
Foundation Medicine Inc, Key Competitors 36
Foundation Medicine Inc, Key Employees 37
Foundation Medicine Inc, Other Locations 38
【免責事項】
http://www.globalresearch.jp/disclaimer